ME02584B - Farmaceutske kompozicije za terapiju zamene glukokortikoida - Google Patents

Farmaceutske kompozicije za terapiju zamene glukokortikoida

Info

Publication number
ME02584B
ME02584B MEP-2016-250A MEP25016A ME02584B ME 02584 B ME02584 B ME 02584B ME P25016 A MEP25016 A ME P25016A ME 02584 B ME02584 B ME 02584B
Authority
ME
Montenegro
Prior art keywords
hydrocortisone
tablet
dosage form
use according
core
Prior art date
Application number
MEP-2016-250A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Stanko Skrtic
Jörgen Johnsson
Hans Lennernäs
Thomas Hedner
Gudmundur Johannsson
Original Assignee
Shire Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc
Publication of ME02584B publication Critical patent/ME02584B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
MEP-2016-250A 2004-04-22 2005-04-21 Farmaceutske kompozicije za terapiju zamene glukokortikoida ME02584B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56420504P 2004-04-22 2004-04-22
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy
PCT/EP2005/004400 WO2005102271A2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
EP05735076.1A EP1744730B1 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy

Publications (1)

Publication Number Publication Date
ME02584B true ME02584B (me) 2017-06-20

Family

ID=35197481

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-250A ME02584B (me) 2004-04-22 2005-04-21 Farmaceutske kompozicije za terapiju zamene glukokortikoida

Country Status (25)

Country Link
US (3) US8425937B2 (enExample)
EP (2) EP1744730B1 (enExample)
JP (2) JP5149618B2 (enExample)
CN (2) CN1942176B (enExample)
AU (1) AU2005235370B2 (enExample)
BR (1) BRPI0510044B8 (enExample)
CA (1) CA2564000C (enExample)
CY (2) CY1118275T1 (enExample)
DK (2) DK3072507T3 (enExample)
ES (2) ES2600556T3 (enExample)
HR (2) HRP20161380T1 (enExample)
HU (2) HUE030546T2 (enExample)
IL (2) IL178776A (enExample)
LT (2) LT3072507T (enExample)
ME (1) ME02584B (enExample)
MX (2) MXPA06012011A (enExample)
NZ (1) NZ585340A (enExample)
PL (2) PL3072507T3 (enExample)
PT (2) PT3072507T (enExample)
RS (2) RS61501B1 (enExample)
SE (1) SE0401031D0 (enExample)
SG (1) SG188081A1 (enExample)
SI (1) SI3072507T1 (enExample)
WO (1) WO2005102271A2 (enExample)
ZA (1) ZA200609680B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
PL1744760T3 (pl) * 2004-04-22 2015-04-30 Acucort Ab Kompozycja farmaceutyczna do ostrego leczenia glikokortykosteroidami
EP1971312A1 (en) * 2005-12-06 2008-09-24 MonoSol Rx LLC Topical film compositions for delivery of actives
FR2926722B1 (fr) * 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
EP2151235B1 (de) * 2008-07-21 2011-02-16 Dr. Falk Pharma Gmbh Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes
US20120183610A1 (en) * 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
MX337429B (es) * 2010-05-20 2016-03-04 Duocort Pharma Ab Posologia y administracion de composiciones basadas en glucocortticoides.
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2014086673A (ja) 2012-10-26 2014-05-12 Mitsubishi Electric Corp モノリシック集積回路
HUE056810T2 (hu) 2012-11-02 2022-03-28 Murray & Poole Entpr Ltd Szív- és érrendszeri események kezelése és megelõzése kolchicin alkalmazásával
HRP20210963T1 (hr) * 2013-04-16 2021-09-17 Murray & Poole Enterprises, Ltd. Formulacija za kontinuirano otpuštanje kolhicina i postupci priprave istog
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
GB201308933D0 (en) * 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
EP2886108B2 (de) 2013-12-23 2022-11-02 Dr. Falk Pharma Gmbh Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus
ES2906778T3 (es) * 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
RU2748437C2 (ru) * 2019-10-28 2021-05-25 Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
PT745382E (pt) * 1994-01-31 2004-04-30 Yamanouchi Pharma Co Ltd Forma moldada por compressao com solubilidade intra-oral e processo para a sua producao
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6156743A (en) 1999-10-18 2000-12-05 Whitcomb; John E. Method of decreasing fatigue
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
EP1368000A4 (en) 2001-03-13 2004-12-01 Penwest Pharmaceuticals Co CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID
CA2441007C (en) * 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
PL372290A1 (en) 2002-02-07 2005-07-11 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
PL1744760T3 (pl) 2004-04-22 2015-04-30 Acucort Ab Kompozycja farmaceutyczna do ostrego leczenia glikokortykosteroidami
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB0623740D0 (en) 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
US20120183610A1 (en) 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
MX337429B (es) 2010-05-20 2016-03-04 Duocort Pharma Ab Posologia y administracion de composiciones basadas en glucocortticoides.

Also Published As

Publication number Publication date
MXPA06012011A (es) 2007-04-16
AU2005235370B2 (en) 2011-06-09
US20080187586A1 (en) 2008-08-07
EP1744730A2 (en) 2007-01-24
JP5681679B2 (ja) 2015-03-11
BRPI0510044A (pt) 2007-10-16
JP2007533698A (ja) 2007-11-22
ES2857600T3 (es) 2021-09-29
WO2005102271A2 (en) 2005-11-03
SG188081A1 (en) 2013-03-28
US8425937B2 (en) 2013-04-23
MX344197B (es) 2016-12-08
AU2005235370A1 (en) 2005-11-03
CY1118275T1 (el) 2017-06-28
CN103006592B (zh) 2016-03-02
JP2012236846A (ja) 2012-12-06
HRP20210348T1 (hr) 2021-04-16
IL227375A (en) 2017-08-31
BRPI0510044B1 (pt) 2019-01-29
HRP20161380T1 (hr) 2016-12-02
IL178776A0 (en) 2007-02-11
DK3072507T3 (da) 2021-02-08
HK1179525A1 (zh) 2013-10-04
BRPI0510044B8 (pt) 2021-05-25
HUE053248T2 (hu) 2021-06-28
EP3072507A1 (en) 2016-09-28
WO2005102271A3 (en) 2006-08-03
CN103006592A (zh) 2013-04-03
CY1124074T1 (el) 2022-03-24
PT3072507T (pt) 2021-02-23
HUE030546T2 (en) 2017-05-29
EP3072507B1 (en) 2020-12-23
PL1744730T3 (pl) 2017-01-31
PT1744730T (pt) 2016-10-07
LT3072507T (lt) 2021-02-25
EP1744730B1 (en) 2016-08-03
ZA200609680B (en) 2008-08-27
NZ585340A (en) 2012-04-27
RS61501B1 (sr) 2021-03-31
CN1942176A (zh) 2007-04-04
US10583146B2 (en) 2020-03-10
RS55198B1 (sr) 2017-01-31
CA2564000A1 (en) 2005-11-03
SI3072507T1 (sl) 2021-04-30
DK1744730T3 (en) 2016-08-29
CA2564000C (en) 2013-07-02
CN1942176B (zh) 2013-09-18
US20140242167A1 (en) 2014-08-28
LT1744730T (lt) 2016-10-25
US20130129823A1 (en) 2013-05-23
IL178776A (en) 2013-10-31
JP5149618B2 (ja) 2013-02-20
PL3072507T3 (pl) 2021-07-19
ES2600556T3 (es) 2017-02-09
SE0401031D0 (sv) 2004-04-22

Similar Documents

Publication Publication Date Title
ME02584B (me) Farmaceutske kompozicije za terapiju zamene glukokortikoida
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2011105733A5 (enExample)
JP2009525985A5 (enExample)
JP2009530385A5 (ja) うつ病の治療のためのケタミンの投与
HRP20231142T3 (hr) Kontrolirano oslobađanje 25-hidroksivitamina d
JP2008044951A5 (enExample)
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
HRP20220929T3 (hr) Sastav za inhalaciju koji sadrži aklidinij za liječenje astme
JP2015531373A5 (enExample)
JP2013516493A5 (enExample)
JP2010501576A5 (enExample)
TW200738228A (en) Neramexane modified release matrix tablet
EA200802350A2 (ru) Система доставки лекарств
MX2007004987A (es) Nuevas formulaciones de tabletas de liberacion modificada para inhibidores de bomba de protones.
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
UY30636A1 (es) Composision farmaceutica de liberacon modificada de un musculo relajante y un aine
HRP20161470T1 (hr) Smjese flurbiprofena s kontroliranim otpuštanjem i mišićnog relaksanta
HRP20110250T1 (hr) Optimalizacija liječenja philadelphia-pozitivne leukemije s imatinibom inhibitorom abl-tirozin kinaze
Miller et al. Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial [ISRCTN38432711]
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении
JP2004521951A5 (enExample)
RS52672B2 (sr) Tretman reumatoidnih bolesti glukokortikoidom sa odloženim-oslobađanjem